Vectura Group plc – LSE:VEC.L

Vectura Group stock price today

GBP 164.8
Financial Health
0
1
2
3
4
5
6
7
8
9

Vectura Group stock price yearly change

+43.30%
year

Vectura Group key metrics

Market Cap
 N/A
Enterprise value
 107.35B
P/E
 0.08
EV/Sales
 617.53
EV/EBITDA
 2998.84
Price/Sales
 6.17
Price/Book
 1.97
PEG ratio
 N/A
EPS
 -0.06
Revenue
 173.85M
EBITDA
 35.8M
Income
 -38.62M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 -22.22%
Oper. margin
 -23.99%
Gross margin
 55.34%
EBIT margin
 -23.99%
EBITDA margin
 20.59%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Vectura Group stock price history

Vectura Group stock forecast

Vectura Group financial statements

Profit Margin

Vectura Group plc (LSE:VEC.L): Profit margin
Jun 2018 40.12M -22.05M -54.95%
Jan 2019 44.57M -5.52M -12.39%
Mar 2019 44.57M -5.52M -12.39%
Jun 2019 44.57M -5.52M -12.39%
VEC.L income statement history
0%
Yield TTM
Vectura Group plc (LSE:VEC.L): Payout ratio
Payout ratio 0%
Vectura Group plc (LSE:VEC.L): Dividend Yield
2016
2017
2018
2019 3.67%
2020
VEC.L dividends history

Debt to Assets

Vectura Group plc (LSE:VEC.L): Debt to assets
Jun 2019 594500000 114.9M 19.33%
Dec 2019 530700000 111.3M 20.97%
Jun 2020 546400000 111M 20.31%
Dec 2020 666000000 121.6M 18.26%
VEC.L balance sheet history

Cash Flow

Vectura Group plc (LSE:VEC.L): Cash Flow
Jun 2018 7.52M -3.07M -3.7M
Jan 2019 5.1M -1.8M -11.05M
Mar 2019 5.1M -1.8M -11.05M
Jun 2019 5.1M -1.8M -11.05M
VEC.L cash flow history

Vectura Group alternative data

Vectura Group
Employees

Vectura Group plc (LSE:VEC.L): Employee count
Aug 2023 502
Sep 2023 502
Oct 2023 502
Nov 2023 502
Dec 2023 502
Jan 2024 502
Feb 2024 502
Mar 2024 502
Apr 2024 502
May 2024 502
Jun 2024 502
Jul 2024 502

Vectura Group other data

Frequently Asked Questions (FAQ)

  • What's the price of Vectura Group stock today?

    One share of Vectura Group stock can currently be purchased for approximately $164.8.

  • When is Vectura Group's next earnings date?

    Unfortunately, Vectura Group's (VEC.L) next earnings date is currently unknown.

  • Does Vectura Group pay dividends?

    No, Vectura Group does not pay dividends.

  • What is Vectura Group's stock symbol?

    Vectura Group plc is traded on the LSE under the ticker symbol "VEC.L".

  • What is Vectura Group's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - General industry.

  • How do i buy shares of Vectura Group?

    Shares of Vectura Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Vectura Group have?

    As Jul 2024, Vectura Group employs 502 workers.

  • When Vectura Group went public?

    Vectura Group plc is publicly traded company for more then 21 years since IPO on 2 Jul 2004.

  • What is Vectura Group's official website?

    The official website for Vectura Group is vectura.com.

  • Where are Vectura Group's headquarters?

    Vectura Group is headquartered at Unit 1, Prospect West, Bumpers Way, Chippenham, WILTSHIRE.

  • How can i contact Vectura Group?

    Vectura Group's mailing address is Unit 1, Prospect West, Bumpers Way, Chippenham, WILTSHIRE and company can be reached via phone at +44 1249 667700.

Vectura Group company profile:

Vectura Group plc

vectura.com
Exchange:

LSE

Full time employees:

502

Industry:

Drug Manufacturers - General

Sector:

Healthcare

Vectura Group Plc engages in the provision of pharmaceutical development. The company is headquartered in Chippenham, Wiltshire and currently employs 453 full-time employees. The firm's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

+44 1249 667700
Unit 1, Prospect West, Bumpers Way
Chippenham, WILTSHIRE

:
ISIN: GB00BKM2MW97
CUSIP: G9325J118